# US 2026/0083656 A1 · Compositions and methods relating to stimulation of hyaluronic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083656 A1
- Document ID: US20260083656A1
- Status: Published application
- Kind: A1
- Application number: 19/064,198
- Filed: 2025-02-26
- Published: 2026-03-26
- Earliest claimed: 2020-10-08
- Assignees: Alastin Skincare, Inc.
- Applicants: Alastin Skincare, Inc.
- Inventors: Alan David Widgerow; John A. Garruto
- Web page: https://patentgrep.com/patent/US20260083656A1

## CPC

- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61G 19/00: Hoisting or lowering devices for coffins
- A61K 8/14: Liposomes; Vesicles
- A61K 8/35: Ketones, e.g. benzophenone
- A61K 8/55: Phosphorus compounds
- A61K 8/553: {Phospholipids, e.g. lecithin}
- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 8/88: Polyamides
- A61K 8/9728: Fungi, e.g. yeasts
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/785: Polymers containing nitrogen
- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- C07K 7/06: having 5 to 11 amino acids
- A61K 2800/10: General cosmetic use
- A61K 2800/78: Enzyme modulators, e.g. Enzyme agonists
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61G: TRANSPORT, PERSONAL CONVEYANCES OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS (appliances for aiding patients or disabled persons to walk A61H3/00); OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES (embalming corpses A01N1/00)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods for stimulating intrinsic hyaluronic acid production are provided herein. Compositions and methods for stimulating intrinsic hyaluronic acid production can improve skin moisture and elasticity.

## Claims

### Claim 1

An octapeptide consisting of the sequence GPHGVREA (SEQ ID NO:5).

### Claim 2

A composition, comprising:
an octapeptide consisting of the sequence GPHGVREA (SEQ ID NO:5); and
a pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

The composition of claim 2, comprising 0.25 ppm to 100 ppm of the octapeptide.

### Claim 4 (depends on 2)

The composition of claim 2, comprising 1 ppm to 30 ppm of the octapeptide.

### Claim 5 (depends on 2)

The composition of claim 2, further comprising a hexapeptide.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the hexapeptide is hexapeptide-12.

### Claim 7 (depends on 6)

The composition of claim 6, comprising 0.25 ppm to 25 ppm of the hexapeptide-12.

### Claim 8 (depends on 5)

The composition of claim 5, wherein the hexapeptide is hexapeptide-11.

### Claim 9 (depends on 2)

The composition of claim 2, further comprising a tripeptide.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the tripeptide is tripeptide-1.

### Claim 11 (depends on 10)

The composition of claim 10, comprising 0.25 ppm to 25 ppm of the tripeptide-1.

### Claim 12

A method for promoting cellular production of hyaluronic acid (HA) in skin comprising human fibroblasts, the method comprising:
administering to the skin an effective amount of an octapeptide consisting of the sequence GPHGVREA (SEQ ID NO:5).

### Claim 13 (depends on 5)

The method of claim 5, wherein the octapeptide promotes production of hyaluronic acid synthase 2 (HAS2).

### Claim 14 (depends on 12)

The method of claim 12, wherein the hyaluronic acid has a molecular weight of about 2 MDa or greater.

### Claim 15 (depends on 12)

The method of claim 12, wherein the octapeptide is administered in a composition comprising 0.25 ppm to 100 ppm of the octapeptide.

### Claim 16 (depends on 15)

The method of claim 15, wherein the composition comprises 20 ppm to 100 ppm of the octapeptide.

### Claim 17 (depends on 15)

The method of claim 15, wherein the composition further comprises a tripeptide.

### Claim 18 (depends on 15)

The method of claim 15, wherein the composition further comprises a hexapeptide.

### Claim 19 (depends on 12)

The method of claim 12, wherein administering the octapeptide improves one or more of the following:
skin hydration;
appearance of age spots;
appearance of white pseudoscars;
appearance of an uneven skin tone; or
appearance of wrinkles.

### Claim 20 (depends on 12)

The method of claim 12, wherein the administering is performed before, during, or after the injection of a filler.
